ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDXC
CUSIPN/A
Phone949-419-0288
Debt
Debt-to-Equity Ratio0.01
Current Ratio5.22
Quick Ratio4.71
Price-To-Earnings
Trailing P/E Ratio-12.51
Forward P/E Ratio-8.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.20 million
Price / Sales11.34
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book4.38
Profitability
EPS (Most Recent Fiscal Year)($0.35)
Net Income$-11,370,000.00
Net Margins-70.19%
Return on Equity-56.28%
Return on Assets-46.19%
Miscellaneous
Employees74
Outstanding Shares54,870,000
Market Cap$242.51
Chromadex (NASDAQ:CDXC) Frequently Asked Questions
What is Chromadex's stock symbol?
Chromadex trades on the NASDAQ under the ticker symbol "CDXC."
How were Chromadex's earnings last quarter?
Chromadex Corp (NASDAQ:CDXC) announced its earnings results on Thursday, May, 10th. The company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.09. The company had revenue of $6.57 million for the quarter, compared to analysts' expectations of $6.50 million. Chromadex had a negative return on equity of 56.28% and a negative net margin of 70.19%. View Chromadex's Earnings History.
When is Chromadex's next earnings date?
What price target have analysts set for CDXC?
2 brokerages have issued twelve-month price targets for Chromadex's shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Chromadex's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 71.2% from the stock's current price. View Analyst Ratings for Chromadex.
What is the consensus analysts' recommendation for Chromadex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Chromadex stock?
Here are some recent quotes from research analysts about Chromadex stock:
- 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (4/17/2018)
- 2. HC Wainwright analysts commented, "We note that the company’s revenues came in at $5.3M vs. our original forecast of $8M, while a net loss of $2.7M or $0.07 per share was also recorded vs. our projection for a positive EPS of $0.04. While R&D spending in the quarter was roughly in-line with our estimate at $728K vs. $700K, we note that COGS were slightly worse than our estimate, coming in at 57% vs. our projection of 49%. Given what we see as the current status of ChromaDex’s ingredients business, we have revised our 2017 revenue number to $24.3M, while we now project a net loss per share for 2017 of $0.14 vs. our prior forecast for EPS of $0.16 for the year." (8/11/2017)
Who are some of Chromadex's key competitors?
Some companies that are related to Chromadex include Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG), Entia Biosciences (ERGO), True Drinks Holdings, Inc Common Stock (TRUU) and Rock Creek Pharmaceuticals (RCPIQ).
Who are Chromadex's key executives?
Chromadex's management team includes the folowing people:
- Mr. Frank Louis Jaksch Jr., Co-Founder, CEO & Director (Age 50)
- Mr. Robert N. Fried, Pres, COO & Director (Age 58)
- Mr. Kevin M. Farr, Chief Financial Officer (Age 60)
- Mr. Troy Allen Rhonemus, Exec. VP (Age 45)
- Andrew Johnson, Director of Investor Relations
Has Chromadex been receiving favorable news coverage?
News articles about CDXC stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chromadex earned a coverage optimism score of 0.20 on Accern's scale. They also gave news stories about the company an impact score of 47.78 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Chromadex's major shareholders?
Chromadex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include North Star Investment Management Corp. (0.13%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer and Stephen R Allen. View Institutional Ownership Trends for Chromadex.
Which institutional investors are selling Chromadex stock?
How do I buy shares of Chromadex?
Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chromadex's stock price today?
One share of CDXC stock can currently be purchased for approximately $4.38.
How big of a company is Chromadex?
Chromadex has a market capitalization of $242.51 million and generates $21.20 million in revenue each year. The company earns $-11,370,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Chromadex employs 74 workers across the globe.
How can I contact Chromadex?
Chromadex's mailing address is 10005 Muirlands Blvd. Suite G, IRVINE CA, 92618. The company can be reached via phone at 949-419-0288 or via email at [email protected]
MarketBeat Community Rating for Chromadex (NASDAQ CDXC)
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
